PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 32, issue 12, 2014

Cost of Illness: An Ongoing Battle Worth Fighting pp. 1151-1152

Paul Greenberg

“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies pp. 1153-1155

Steven Kymes

A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials pp. 1157-1170

Rita Faria, Manuel Gomes, David Epstein and Ian White

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal pp. 1171-1183

Nicholas Latimer, Christopher Carroll, Ruth Wong, Paul Tappenden, Michael Venning and Raashid Luqmani

A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions pp. 1185-1199

Rachel Elliott, Koen Putman, James Davies and Lieven Annemans

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments pp. 1201-1212

Andrew Messali, Reginald Villacorta and Joel Hay

The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review pp. 1213-1229

Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Michael Byrnes, Karin Travers and Chris Pashos

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer pp. 1231-1243

Steven Alberts, Tiffany Yu, Robert Behrens, Lindsay Renfro, Geetika Srivastava, Gamini Soori, Shaker Dakhil, Rex Mowat, John Kuebler, George Kim, Miroslaw Mazurczak and John Hornberger

Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines” pp. 1245-1246

Afschin Gandjour

Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines” pp. 1247-1247

A. Newall, M. Jit and R. Hutubessy

Objectivity and Equity: Clarity Required. A Response to Hill and Olson pp. 1249-1250

Mike Paulden, James O’Mahony, Anthony Culyer and Christopher McCabe

Volume 32, issue 11, 2014

Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies? pp. 1035-1037

Surrey Walton and Glen Schumock

NICE, Social Values, and Balancing Objectivity and Equity pp. 1039-1041

Suzanne Hill and Leslie Olson

Some Inconsistencies in NICE’s Consideration of Social Values pp. 1043-1053

Mike Paulden, James O’Mahony, Anthony Culyer and Christopher McCabe

Through a Glass Darkly: Economics and Personalised Medicine pp. 1055-1061

Alan Haycox, Munir Pirmohamed, Claire McLeod, Rachel Houten and Sarah Richards

Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome pp. 1063-1078

Fotini Gialama, Evangelia Miloni and Nikos Maniadakis

Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review pp. 1079-1091

Patrick Zueger, Neil Schultz and Todd Lee

The Health Economics of Bladder Cancer: An Updated Review of the Published Literature pp. 1093-1104

Christina Yeung, Tuan Dinh and Joseph Lee

A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States pp. 1105-1114

Bijal Patel and Patricia Audet

Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment pp. 1115-1127

Peter Ghijben, Emily Lancsar and Silva Zavarsek

Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease pp. 1129-1139

Shien Guo, Denis Getsios, Nikhil Revankar, Peng Xu, Gwilym Thompson, Joel Bobula, Loretto Lacey and Maren Gaudig

The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees pp. 1141-1145

Manuel Arias and Francisco Díez

Volume 32, issue 10, 2014

Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary pp. 937-942

Robin Gauld

Decision-Analytic Models: Current Methodological Challenges pp. 943-950

J. Caro and Jörgen Möller

Reconceptualising the External Validity of Discrete Choice Experiments pp. 951-965

Emily Lancsar and Joffre Swait

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models pp. 967-979

Paul Tappenden and James Chilcott

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility pp. 981-993

Kevin Marsh, Peng Xu, Panagiotis Orfanos, James Gordon and Ingolf Griebsch

Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes pp. 995-1004

Zafar Zafari, Kristian Thorlund, J. FitzGerald, Carlo Marra and Mohsen Sadatsafavi

Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer pp. 1005-1013

David Lairson, Rohan Parikh, Janice Cormier, Wenyaw Chan and Xianglin Du

Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis pp. 1015-1028

An Tran-Duy, Annelies Boonen, Wietske Kievit, Piet Riel, Mart Laar and Johan Severens

Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider pp. 1029-1029

Matt Stevenson and Peter Selby

Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary” pp. 1031-1033

Scott Metcalfe, Rachel Grocott and Dilky Rasiah

Volume 32, issue 9, 2014

Hospital-Based Health Technology Assessment: Insights from New Zealand pp. 815-817

Stephen Munn

Hospital-Based Health Technology Assessment: Developments to Date pp. 819-824

Marie-Pierre Gagnon

HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes pp. 825-839

Véronique Raimond, Jean-Michel Josselin and Lise Rochaix

The Burden of Disease in Rheumatoid Arthritis pp. 841-851

Till Uhlig, Rikke Moe and Tore Kvien

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges pp. 853-864

Kevin Marsh, Peng Xu, Panagiotis Orfanos, Agnes Benedict, Kamal Desai and Ingolf Griebsch

The Economic Burden of Head and Neck Cancer: A Systematic Literature Review pp. 865-882

Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Talia Foster and Chris Pashos

Discrete Choice Experiments in Health Economics: A Review of the Literature pp. 883-902

Michael Clark, Domino Determann, Stavros Petrou, Domenico Moro and Esther Bekker-Grob

Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada pp. 903-917

Anita Brogan, Erik Smets, Josephine Mauskopf, Sarah Manuel and Ines Adriaenssen

Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain pp. 919-936

Antonio Gómez-Outes, Cristina Avendaño-Solá, Ana Terleira-Fernández and Emilio Vargas-Castrillón

Volume 32, issue 8, 2014

Transparency in Reimbursement Decisions: In Whose Best Interest? pp. 725-727

Tania Stafinski and Devidas Menon

Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA? pp. 729-733

James Chambers

Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider pp. 735-743

Matt Stevenson and Peter Selby

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management pp. 745-758

Andrew Gawron, Dustin French, John Pandolfino and Colin Howden

A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis pp. 759-773

Ayse Kuspinar and Nancy Mayo

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK pp. 775-787

Alex Diamantopoulos, A. Finckh, T. Huizinga, D. Sungher, L. Sawyer, David Neto and F. Dejonckheere

The Better than Dead Method: Feasibility and Interpretation of a Valuation Study pp. 789-799

R. Hoorn, A. Donders, M. Oppe and P. Stalmeier

A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding pp. 801-813

Rosarin Sruamsiri, Piyameth Dilokthornsakul, Chayanin Pratoomsoot and Nathorn Chaiyakunapruk

Volume 32, issue 7, 2014

NICE’s Cost-Effectiveness Range: Should it be Lowered? pp. 613-615

J. Raftery

Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs pp. 617-626

R. Diel and N. Lampenius

Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease pp. 627-637

Laura Burgers, William Redekop and Johan Severens

A Review of the Economics of Treating Clostridium difficile Infection pp. 639-650

Kari Mergenhagen, Amy Wojciechowski and Joseph Paladino

Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review pp. 651-680

Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel Geynisman and Ya-Chen Shih

Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study pp. 681-691

Pieter Dylst, Arnold Vulto and Steven Simoens

Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales pp. 693-706

Kamran Khan, Stavros Petrou, Oliver Rivero-Arias, Stephen Walters and Spencer Boyle

Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand pp. 707-724

Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland and Tony Blakely

Volume 32, issue 6, 2014

Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis? pp. 521-523

Josephine Mauskopf

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines pp. 525-531

A. Newall, M. Jit and R. Hutubessy

Methods for Adjusting for Bias Due to Crossover in Oncology Trials pp. 533-546

K. Ishak, Irina Proskorovsky, Beata Korytowsky, Rickard Sandin, Sandrine Faivre and Juan Valle

When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES pp. 547-558

Jonathan Karnon and Hossein Haji Ali Afzali

Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches pp. 559-572

Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez and Anuraag Kansal

Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER) pp. 573-590

Rachel Elliott, Koen Putman, Matthew Franklin, Lieven Annemans, Nick Verhaeghe, Martin Eden, Jasdeep Hayre, Sarah Rodgers, Aziz Sheikh and Anthony Avery

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? pp. 591-599

Klazien Matter-Walstra, Dirk Klingbiel, Thomas Szucs, Bernhard Pestalozzi and Matthias Schwenkglenks

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation pp. 601-612

Torbjørn Wisløff, Gunhild Hagen and Marianne Klemp

Volume 32, issue 5, 2014

Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now pp. 425-427

Wei Zhang and Aslam Anis

How to Select the Right Cost-Effectiveness Model? pp. 429-442

H. Haalen, J. Severens, A. Tran-Duy and A. Boonen

Is Individualized Medicine More Cost-Effective? A Systematic Review pp. 443-455

Maximilian Hatz, Katharina Schremser and Wolf Rogowski

Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden pp. 457-466

Tracy Skaer

Cost and Cost Effectiveness of Vaginal Progesterone Gel in Reducing Preterm Birth: An Economic Analysis of the PREGNANT Trial pp. 467-478

Laura Pizzi, Neil Seligman, Jason Baxter, Eric Jutkowitz and Vincenzo Berghella

Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium pp. 479-493

Lieven Annemans, Mélanie Brignone, Sylvain Druais, Ann Pauw, Aline Gauthier and Koen Demyttenaere

Valuation of EQ-5D-3L Health States in Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health States pp. 495-507

Nan Luo, Pei Wang, Julian Thumboo, Yee-Wei Lim and Hubertus Vrijhoef

A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France pp. 509-520

Michael Drummond, Gerard Pouvourville, Elizabeth Jones, Jennifer Haig, Grece Saba and Hélène Cawston

Volume 32, issue 4, 2014

Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice? pp. 315-318

Mike Paulden, Christopher McCabe and Jonathan Karnon

Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room pp. 319-325

Simon Eckermann and Brita Pekarsky

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin pp. 327-334

Roberta Longo, Paul Baxter, Peter Hall, Jenny Hewison, Mehran Afshar, Geoff Hall and Christopher McCabe

How to Estimate Productivity Costs in Economic Evaluations pp. 335-344

Marieke Krol and Werner Brouwer

Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature pp. 345-365

Kevin Marsh, Tereza Lanitis, David Neasham, Panagiotis Orfanos and Jaime Caro

Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010 pp. 367-375

Torbjørn Wisløff, Gunhild Hagen, Vida Hamidi, Espen Movik, Marianne Klemp and Jan Olsen

A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention pp. 377-393

Maximilian Hatz, Reiner Leidl, Nichola Yates and Björn Stollenwerk

Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines pp. 395-409

Josephine Mauskopf, Miny Samuel, Doreen McBride, Usha Mallya and Steven Feldman

Differential Time Preferences for Money and Quality of Life pp. 411-419

M. Parouty, H. Le, D. Krooshof and M. Postma

Response to Letter to Editor: Capturing Disutility from Waiting Time pp. 421-422

Victoria Brennan and Simon Dixon

Capturing Disutility from Waiting Time pp. 423-424

Afschin Gandjour

Volume 32, issue 3, 2014

The Role of Health Economics and Outcomes Research in Health Care Reform in China pp. 231-234

Wannian Liang, Jipan Xie, Hongpeng Fu and Eric Wu

Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer pp. 235-243

Tan Chongqing, Peng Liubao, Zeng Xiaohui, Li Jianhe, Wan Xiaomin, Chen Gannong, Wang Siying, Ouyang Lihui and Zhao Ziying

Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program pp. 245-255

Mingsheng Chen, Lijie Wang, Wen Chen, Luying Zhang, Hongli Jiang and Wenhui Mao

Time Trends and Determinants of Pharmaceutical Expenditure in China (1990–2009) pp. 257-264

Lizheng Shi, Heidi Yang, Gang Cheng and Qingyue Meng

Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China pp. 265-275

Suwei Yuan, Yan Liu, Na Li, Yunting Zhang, Zhe Zhang, Jingjing Tao, Lizheng Shi, Hude Quan, Mingshan Lu and Jin Ma

The Impact of the Urban Resident Basic Medical Insurance on Health Services Utilisation in China pp. 277-292

Gang Chen, Gordon Liu and Fei Xu

Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals pp. 293-303

Jing Wu, Judy Xu, Gordon Liu and Jiuhong Wu

Treatment, Monitoring, and Economic Outcomes of Venous Thromboembolism Among Hospitalized Patients in China pp. 305-313

Eric Wu, Jipan Xie, Chun Wu, Ella Du, Nanxin Li, Ruoding Tan and Yuanli Liu

Volume 32, issue 2, 2014

Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial pp. 101-108

Vakaramoko Diaby, Georges Adunlin and Alberto Montero

Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models pp. 109-134

Eleanor Heather, Katherine Payne, Mark Harrison and Deborah Symmons

Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer pp. 135-147

Malek Hannouf, Bin Xie, Muriel Brackstone and Gregory Zaric

Clinical and Economic Impact of Substituting Dexmedetomidine for Propofol due to a US Drug Shortage: Examination of Coronary Artery Bypass Graft Patients at an Urban Medical Centre pp. 149-157

Brandi Thoma, Julius Li, Cara McDaniel, Cindy Wordell, Nicholas Cavarocchi and Laura Pizzi

The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis pp. 159-172

Paul Tappenden, Sue Harnan, Lesley Uttley, Matthew Mildred, Martin Walshaw, Christopher Taylor and Keith Brownlee

The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer pp. 173-191

J. Jayasekera, E. Onukwugha, K. Bikov, C. Mullins, B. Seal and A. Hussain

Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse pp. 193-207

Michael Adena, Jennifer Houltram, Stephen Mulligan, Carlene Todd and Grace Malanos

Eliciting Preferences to Inform Patient-Centred Policies: the Case of Psoriasis pp. 209-223

Aleksandra Torbica, Giovanni Fattore and Fabio Ayala

On the Use and Interpretation of Quantile Regression in Quality-of-Life Research pp. 225-227

Leonardo Koeser and Paul McCrone

The Authors’ Reply to Koeser and McCrone: “On the Use and Interpretation of Quantile Regression in Quality-of-Life Research” pp. 229-230

Michela Tinelli, Anthony Scott, Janelle Seymour, Mandy Ryan, Christine Bond and Paul McNamee

Volume 32, issue 1, 2014

Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment? pp. 1-4

Janine Til and Maarten IJzerman

Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences pp. 5-13

Jeffrey Barletta and David Sclar

Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus pp. 15-27

Carl Asche, Stephen Hippler and Dean Eurich

Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies pp. 29-45

Katelijne Vooren, Silvy Duranti, Alessandro Curto and Livio Garattini

The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance pp. 47-61

Gerardus Frederix, Johan Hasselt, Jan Schellens, Anke Hövels, Jan Raaijmakers, Alwin Huitema and Johan Severens

Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare pp. 63-74

Fadia Shaya, Ian Breunig, Brian Seal, C. Mullins, Viktor Chirikov and Nader Hanna

The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk pp. 75-86

Ana Bobinac, Job van Exel, Frans Rutten and Werner Brouwer

Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial pp. 87-99

Edward Wilson, Ludmila Shulgina, Anthony Cahn, Edwin Chilvers, Helen Parfrey, Allan Clark, Orion Twentyman and Andrew Wilson